JP2006503914A - ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法 - Google Patents

ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP2006503914A
JP2006503914A JP2005501623A JP2005501623A JP2006503914A JP 2006503914 A JP2006503914 A JP 2006503914A JP 2005501623 A JP2005501623 A JP 2005501623A JP 2005501623 A JP2005501623 A JP 2005501623A JP 2006503914 A JP2006503914 A JP 2006503914A
Authority
JP
Japan
Prior art keywords
hpv
protein
polypeptide
individual
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005501623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503914A5 (https=
Inventor
キャスリーン ビーチ
マリー リン ヘドリー
ロバート ジー． アーバン
ローマン エム． シックズ
Original Assignee
エムジーアイ ファーマ バイオロジックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エムジーアイ ファーマ バイオロジックス インコーポレイテッド filed Critical エムジーアイ ファーマ バイオロジックス インコーポレイテッド
Publication of JP2006503914A publication Critical patent/JP2006503914A/ja
Publication of JP2006503914A5 publication Critical patent/JP2006503914A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2005501623A 2002-10-21 2003-10-16 ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法 Pending JP2006503914A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42006802P 2002-10-21 2002-10-21
US47148103P 2003-05-15 2003-05-15
PCT/US2003/032705 WO2004037175A2 (en) 2002-10-21 2003-10-16 Compositions and methods for treating human papillomavirus-mediated disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010275323A Division JP2011121946A (ja) 2002-10-21 2010-12-10 ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2006503914A true JP2006503914A (ja) 2006-02-02
JP2006503914A5 JP2006503914A5 (https=) 2006-08-17

Family

ID=32179780

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2005501623A Pending JP2006503914A (ja) 2002-10-21 2003-10-16 ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
JP2010275323A Pending JP2011121946A (ja) 2002-10-21 2010-12-10 ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010275323A Pending JP2011121946A (ja) 2002-10-21 2010-12-10 ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法

Country Status (8)

Country Link
US (2) US20060247190A1 (https=)
EP (1) EP1556513B1 (https=)
JP (2) JP2006503914A (https=)
AT (1) ATE465753T1 (https=)
AU (2) AU2003284239B2 (https=)
CA (1) CA2502696A1 (https=)
DE (1) DE60332377D1 (https=)
WO (1) WO2004037175A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015012874A (ja) * 2006-07-28 2015-01-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
JP2023062338A (ja) * 2021-10-21 2023-05-08 国立大学法人神戸大学 がんワクチン

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46453E1 (en) * 2006-04-19 2017-06-27 Postech Foundation Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
BRPI0710242A2 (pt) * 2006-04-21 2011-08-09 Transgene Sa uso de uma composição
EP2013230A2 (en) * 2006-04-21 2009-01-14 Transgene S.A. Hpv-16-based papillomavirus vaccine
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
EP2276495B1 (en) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
EP2601968A1 (en) 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum HPV derived polynucleic acids for therapy
CA2876656C (en) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
CA3005251A1 (en) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2018060288A1 (en) * 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
EP3600395A4 (en) 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
CA3058807A1 (en) * 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
WO2019113200A1 (en) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
WO2020117715A1 (en) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Oligo-benzamide analogs and their use in cancer treatment
WO2021026335A1 (en) * 2019-08-08 2021-02-11 The Trustees Of Indiana University Methods for identifying and treating urinary tract infections
CN112957461B (zh) * 2021-02-02 2023-01-10 南开大学 一种形貌可控自佐剂宫颈癌多肽疫苗的制备及性能表征方法
WO2024180232A1 (en) * 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Therapeutic hpv vaccines based on validated target epitopes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019408A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76429T1 (de) * 1986-03-21 1992-06-15 Pasteur Institut Bestimmte, von einem papillomavirus-genom abgeleitete dns-sequenzen, deren anwendungen fuer in vitro-diagnostische zwecke und die herstellung von antigenzusammensetzungen.
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US6007806A (en) * 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5753233A (en) * 1990-05-10 1998-05-19 Behring Diagnostics Gmbh Seroreactive epitopes on proteins of human papilloma-virus (HPV) 18
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US6183745B1 (en) * 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5543294A (en) 1991-07-19 1996-08-06 The Trustees Of Columbia University In The City Of New York Polymerase chain reaction/restriction fragment length polymorphism method for the detection and typing of myobacteria
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6037135A (en) * 1992-08-07 2000-03-14 Epimmune Inc. Methods for making HLA binding peptides and their uses
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
US5462520A (en) 1992-08-17 1995-10-31 Genetronics, Inc. Transsurface drug delivery by electrofusion of microbubbles to the tissue surface
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU692152B2 (en) * 1993-03-17 1998-06-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Immunogenic chimeras comprising nucleic acid sequences encoding endoplasmic reticulum signal sequence peptides and at least one other peptide, and their uses in vaccines and disease treatments
US5993434A (en) 1993-04-01 1999-11-30 Genetronics, Inc. Method of treatment using electroporation mediated delivery of drugs and genes
US5679647A (en) * 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5679509A (en) * 1993-09-28 1997-10-21 University Of New Mexico Methods and a diagnostic aid for distinguishing a subset of HPV that is associated with an increased risk of developing cervical dysplasia and cervical cancer
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
WO1996025507A2 (en) 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods of preparation and use of recombinant adenoviral vectors
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
US5962428A (en) * 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
US5626161A (en) * 1996-04-29 1997-05-06 Fu Tai Umbrella Works, Ltd. Multiple-fold automatic umbrella with simplified reliable control means
AU733719B2 (en) * 1996-10-23 2001-05-24 Trustees Of The University Of Pennsylvania, The Improved vaccines
US20020103145A1 (en) * 1999-05-19 2002-08-01 Adrian Bot Immunization of infants
ATE341339T1 (de) * 1996-12-20 2006-10-15 Merck & Co Inc Zusammensetzungen von rekombinanten papillomavirus vakzinen
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) * 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
GB9722766D0 (en) 1997-10-28 1997-12-24 British Telecomm Portable computers
CA2313641A1 (en) 1997-12-12 1999-06-24 Digene Corporation Universal collection medium
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US6534482B1 (en) * 1998-05-13 2003-03-18 Epimmune, Inc. Expression vectors for stimulating an immune response and methods of using the same
AU771262B2 (en) 1998-08-12 2004-03-18 Eisai Inc. Profiling and cataloging expressed protein tags
SI1108035T1 (sl) * 1998-09-04 2007-12-31 Sanofi Pasteur Ltd Zdravljenje raka materničnega vratu
CA2276066A1 (en) 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
AU1023401A (en) * 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
AU783918B2 (en) 1999-11-19 2005-12-22 Eisai Inc. Continuous-flow method for preparing microparticles
BR0112386A (pt) 2000-06-22 2003-06-10 3M Innovative Properies Compan Sistema e métodos para tratar uma superfìcie mucosal
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019408A1 (en) * 1999-09-16 2001-03-22 Zycos Inc. Nucleic acids encoding polyepitope polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015012874A (ja) * 2006-07-28 2015-01-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改良されたワクチンおよびそれを使用するための方法
JP2023062338A (ja) * 2021-10-21 2023-05-08 国立大学法人神戸大学 がんワクチン

Also Published As

Publication number Publication date
CA2502696A1 (en) 2004-05-06
JP2011121946A (ja) 2011-06-23
AU2003284239A1 (en) 2004-05-13
US20060247190A1 (en) 2006-11-02
EP1556513A4 (en) 2007-03-14
ATE465753T1 (de) 2010-05-15
AU2003284239B2 (en) 2008-08-21
EP1556513A2 (en) 2005-07-27
EP1556513B1 (en) 2010-04-28
WO2004037175A2 (en) 2004-05-06
US20110158952A1 (en) 2011-06-30
DE60332377D1 (de) 2010-06-10
WO2004037175A3 (en) 2004-07-29
AU2008249148A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
JP2011121946A (ja) ヒトパピローマウイルス媒介性疾患を治療するための組成物および方法
JP2006503914A5 (https=)
Yan et al. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen
US20220347292A1 (en) Human cytomegalovirus vaccine
EP1296711B1 (en) Hpv-e7 for human papilloma virus treatment
EP1108035B1 (en) Treatment of cervical cancer
EP2167137B1 (en) Hpv polyepitope constructs and uses thereof
CA2305683C (en) Immunogenic peptides from the hpv e7 protein
JP2004535816A (ja) Ｃｉｎを含むｈｐｖ関連の前癌性増殖および癌性増殖に関する方法および組成物
Cheung et al. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection
JP2004504057A (ja) コドン最適化されたパピローマウイルス配列
TW200840869A (en) Papillomavirus vaccine
TW201941786A (zh) 一種新型多價hpv 疫苗成份
CN103476424A (zh) Cyaa携带的多肽及其在诱导治疗性和预防性免疫应答中的应用
JP2023525558A (ja) 再発性呼吸器乳頭腫症のためのワクチン及びそれを使用する方法
Ayesha et al. Physiopathology and effectiveness of therapeutic vaccines against human papillomavirus
EP3369431A1 (en) Vaccine
CN114409744A (zh) Hpv抗原表位及其鉴定方法、应用
CN116217675B (zh) Hpv抗原表位及其应用
EP1390074B1 (en) Novel compositions and uses therefor
JP2002532434A (ja) パピローマウイルス感染の治療方法
CN114478712B (zh) Hpv抗原表位及其鉴定方法、应用
WO2007033533A1 (en) Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv
AU2019276162B2 (en) Combined prophylactic and therapeutic vaccines
WO2024081892A1 (en) Vaccines for recurrent respiratory papillomatosis and methods of using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060907

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090327

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20091009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100811